Comparing ANI Pharmaceuticals (NASDAQ:ANIP) & Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS – Get Free Report) and ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Zoetis and ANI Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zoetis $9.47 billion 3.61 $2.67 billion $5.88 14.31
ANI Pharmaceuticals $883.37 million 1.81 $78.34 million $5.02 13.99

Zoetis has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.0% of ANI Pharmaceuticals shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zoetis and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zoetis 26.15% 85.90% 18.39%
ANI Pharmaceuticals 11.22% 28.34% 11.18%

Volatility & Risk

Zoetis has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Zoetis and ANI Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis 1 12 8 0 2.33
ANI Pharmaceuticals 0 4 3 0 2.43

Zoetis presently has a consensus price target of $101.25, indicating a potential upside of 20.31%. ANI Pharmaceuticals has a consensus price target of $100.00, indicating a potential upside of 42.40%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Zoetis.

Summary

Zoetis beats ANI Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

About Zoetis

(Get Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.